ERBB2 and breast carcinoma: Nevertheless, only a minimal impact of these factors on the long-term outcomes evaluated in the study can be expected, as the majority of events observed in our study were related to the HER2 + BC of interest, and only one contralateral HER2- BC and one breast cancer-unrelated death were reported.